Apretude (cabotegravir long-acting)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Apretude (cabotegravir long-acting), covering 2025-12-22 to 2025-12-22. Get the full timeline:
Most recent: Clinical Trial Update: Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) [Phase 3]